Healthcare technology companyMasimo recently announced a partnership with Google and Qualcomm to develop a reference platform. The initiative aims to facilitate the introduction of more smartwatches with biomonitoring capabilities.

Joe Kiani, CEO of Masimo, pointed out that the company offers accurate measurements of oxygen saturation (SPO2), heart rate, hydration and heart rate variability. He expressed scepticism aboutApple ‘s ability to provide similar functionality, such as sleep apnoea detection, without using SPO2 measurement, a practice he deemed clinically non-existent.

The CEO also spoke about ongoing litigation with Apple, referring to an injunction that prevents Apple from selling SPO2 devices in the US and a trade secrets case. He said that, if successful, the injunction could extend to preventing Apple from measuring heart rate and detecting arrhythmias.

In addition, Kiani was particularly enthusiastic about the partnership with Google, which will give every Android user access to advanced devices thanks to a jointly-developed reference design. He expects that, in time, a diverse range of products, from luxury items to typical smartwatches, will be launched on the market.

 

Bloomberg videos, provided by MT Newswires